Insulin Action for Plaque Psoriasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial investigates the role of insulin in the development of psoriasis, a skin condition that causes red, scaly patches. Researchers aim to determine if insulin activity differs in psoriasis-affected skin compared to other body areas. Participants will provide skin samples to study these differences. This trial suits individuals with plaque psoriasis interested in exploring the link between their skin condition and insulin.
As an unphased trial, it offers participants a unique opportunity to contribute to foundational research that may uncover new insights into psoriasis and insulin.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've used antidiabetic medications in the last 90 days or certain other medications within 48 hours of the biopsy. It's best to discuss your specific medications with the trial team.
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores the connection between insulin action and psoriasis, offering a fresh perspective on the condition. Unlike standard treatments like topical corticosteroids, systemic medications, and biologics, which primarily target skin inflammation, this study looks at how insulin sensitivity and resistance might influence psoriasis. By examining patients with varying levels of insulin sensitivity, they aim to uncover how insulin could play a role in psoriasis pathogenesis. This could lead to more personalized treatment strategies and potentially open the door to new therapeutic options focusing on metabolic pathways.
Who Is on the Research Team?
Joshua R Cook, MD, PhD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline assessments including fasting blood tests and skin biopsies
Oral Glucose Tolerance Test (OGTT)
Participants undergo OGTT with additional skin biopsies to assess insulin action
Follow-up
Participants are monitored for safety and effectiveness after the OGTT
What Are the Treatments Tested in This Trial?
Interventions
- Oral glucose tolerance test (OGTT)
- Skin punch biopsy
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Patients with plaque psoriasis found to have: * Hemoglobin A1c \< 5.7% * Fasting plasma glucose: \< 95 mg/dL * Fasting serum insulin: \< 10 micro-international units per milliliter (μIU/mL) * 2-hour post-challenge glucose \< 140 mg/dL NOTE: Group assignments made retroactively based on the observational study results.
Patients with plaque psoriasis found to have: * Fasting serum/plasma insulin ≥ 15 μIU/mL * Fasting plasma glucose 80-125 mg/dL and * Hemoglobin A1c \< 6.5% and * 2-hour post-challenge glucose \< 200 mg/dL NOTE: Group assignments made retroactively based on the observational study results.
Patients with plaque psoriasis found to have: * Hemoglobin A1c \< 6.5% * Fasting plasma glucose \<125 mg/dL * Fasting serum insulin: \<15 μIU/mL * 2-hour post-challenge glucose \< 200 mg/dL NOTE: Group assignments made retroactively based on the observational study results. • Not otherwise meeting all criteria for inclusion in the IS group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.